Does Rallies show 13F holders for JAZZ?

Yes. Rallies tracks hedge fund and 13F ownership data for JAZZ, including fund names, share counts, latest tracked quarter, and position changes when available.

Is JAZZ research on Rallies investment advice?

No. Rallies provides research, data, and educational context for JAZZ. It does not provide personalized investment advice.

JAZZ (Jazz Pharmaceuticals, Inc.) Stock Analysis - Hedge Fund Holdings

Jazz Pharmaceuticals, Inc. (JAZZ) is a publicly traded Healthcare sector company. As of May 21, 2026, JAZZ trades at $242.70 with a market cap of $14.40B and a P/E ratio of 26.45. JAZZ moved +0.70% today. Year to date, JAZZ is +37.05%; over the trailing twelve months it is +115.29%. Its 52-week range spans $95.49 to $242.18. Analyst consensus is strong buy with an average price target of $241.43. Rallies surfaces JAZZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns JAZZ stock?

Hedge funds tracked by Rallies that own JAZZ include Baupost Group, Bridgewater Associates, Panagora Asset, Rokos Capital, and Centerbook Partners. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Jazz Pharmaceuticals, Inc..

JAZZ Key Metrics

Key financial metrics for JAZZ
Metric	Value
Price	$242.70
Market Cap	$14.40B
P/E Ratio	26.45
EPS	$9.06
Dividend Yield	0.00%
52-Week High	$242.18
52-Week Low	$95.49
Volume	53
Avg Volume	0
Revenue (TTM)	$4.07B
Net Income	$560.12M
Gross Margin	0.00%

Top Hedge Funds Holding JAZZ

Baupost Group holds 1.27M shares of JAZZ, changed +52.84% as of Jun 30, 2024.
Bridgewater Associates holds 250.95K shares of JAZZ, changed +30.68% as of Mar 31, 2025.
Panagora Asset holds 143.50K shares of JAZZ, changed +52.98% as of Mar 31, 2026.
Rokos Capital holds 52.02K shares of JAZZ, changed +0.00% as of Mar 31, 2026.
Centerbook Partners holds 30.10K shares of JAZZ, changed +0.00% as of Dec 31, 2025.

Latest JAZZ News

Jazz Pharmaceuticals jumps on Q1 revenue surge, EPS beat, and reaffirmed 2026 outlook — May 6, 2026
Jazz Pharmaceuticals Reports 19% Revenue Growth to $1.1B, Zanidatamab Granted Priority Review — May 5, 2026
Jazz Pharmaceuticals rises as ASCO 2026 Ziihera data looms, analyst optimism builds — Apr 27, 2026
Jazz Pharmaceuticals Gets FDA Priority Review, August 25 PDUFA for Ziihera in HER2+ GEA — Apr 27, 2026
Jazz Pharmaceuticals Sets May 5 Q1 Report, Showcases ASCO Data for Ziihera and Zepzelca — Apr 21, 2026

Recent JAZZ Insider Trades

COZADD BRUCE C sold 6.00K (~$1.22M) on May 1, 2026.
COZADD BRUCE C sold 3.68K (~$700.78K) on Apr 1, 2026.
COZADD BRUCE C sold 2.29K (~$437.63K) on Apr 1, 2026.

JAZZ Analyst Consensus

15 analysts cover JAZZ: 0 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $241.43.

Common questions about JAZZ

Who owns JAZZ stock?: Hedge funds tracked by Rallies that own JAZZ include Baupost Group, Bridgewater Associates, Panagora Asset, Rokos Capital, and Centerbook Partners. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Jazz Pharmaceuticals, Inc..
Does Rallies show 13F holders for JAZZ?: Yes. Rallies tracks hedge fund and 13F ownership data for JAZZ, including fund names, share counts, latest tracked quarter, and position changes when available.
Is JAZZ research on Rallies investment advice?: No. Rallies provides research, data, and educational context for JAZZ. It does not provide personalized investment advice.